Sitemap > Breaking Research > Infectious Diseases
Displaying 501 - 550 of 4290 results
- Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002.
- Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers.
- The global status of resistance to antiretroviral drugs.
- The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases.
- Inhibition of protein kinases C prevents murine cytomegalovirus replication.
- Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.
- Opposing effects of CXCR3 and CCR5 deficiency on CD8+ T cell-mediated inflammation in the central nervous system of virus-infected mice.
- CD43 is required for optimal growth inhibition of Mycobacterium tuberculosis in macrophages and in mice.
- The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production.
- Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
- Ribavirin plus interferon versus interferon for chronic hepatitis C.
- A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.
- Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
- Antagonism of HSV-tk transfection and ganciclovir treatment on chemotherapeutic drug sensitivity.
- Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
- Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives.
- Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses.
- Oral immunization with a shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis.
- Streptococcus pyogenes collagen type I-binding Cpa surface protein. Expression profile, binding characteristics, biological functions, and potential clinical impact.
- Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells.
- Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.
- Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.
- Role of heme oxygenase-1 in endotoxemic acute renal failure.
- Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
- Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
- Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
- In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
- Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
- Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
- Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
- Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
- Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.
- Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
- TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
- Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
- Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
- In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
- Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase.
- Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.
- IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.
- Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
- Ion transport blockers inhibit human rhinovirus 2 release.
- Citridones, new potentiators of antifungal miconazole activity, produced by Penicillium sp. FKI-1938. II. Structure elucidation.
- Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. II. Structure elucidation of caprazamycins.
- Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.
- Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists.
- Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
- A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
- Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies.
- A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >